-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $144

Benzinga·08/01/2025 14:12:07
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $146 to $144.